Photo from wikipedia
Myelodysplastic syndromes (MDS) are characterised by ineffective haematopoiesis. Although hypomethylating agents (HMA) have improved survival in higher‐risk MDS, most patients eventually succumb to progressive disease. Utilising samples collected prospectively from… Click to show full abstract
Myelodysplastic syndromes (MDS) are characterised by ineffective haematopoiesis. Although hypomethylating agents (HMA) have improved survival in higher‐risk MDS, most patients eventually succumb to progressive disease. Utilising samples collected prospectively from three MDS clinical trials, we analysed genetic and immunological biomarkers and correlated them with clinical outcomes.
Keywords:
cytokine signalling;
cell cytokine;
mds;
immune cell;
dysregulation immune;
clinical outcomes
Journal Title: European Journal of Haematology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Haematology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!